Phase II Trial of Enzalutamide for Castrate-resistant Prostate Cancer (CRPC) With Correlative Assessment of Androgen Receptor (AR) Signaling and Whole-exome and Transcriptome Sequencing
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 28 Mar 2018
At a glance
- Drugs Enzalutamide (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Pharmacodynamics
- 22 Mar 2018 Planned primary completion date changed from 1 Dec 2017 to 1 May 2018.
- 10 Jun 2017 Biomarkers information updated
- 19 Apr 2017 Planned primary completion date changed from 1 Feb 2017 to 1 Dec 2017.